Alpharma Inc

Alpharma — Investor Day (December 2007)

125 slides from Alpharma's investor day presentation, Dec 18, 2007

  1. Slide 1: Company Strategy and Pharmaceuticals Update

    Company Strategy and Pharmaceuticals Update December 18, 2007 Four Seasons Hotel 57 East 57th Street New York, NY 10022

  2. Slide 2: Welcome

    Welcome Jack Howarth Vice President Investor Relations

  3. Slide 3: Forward Looking Statement

    Forward Looking Statement Statements made in this presentation include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements, including those relating to future financial expectations, involve certain risks and uncertainties that coul

  4. Slide 4: Webcast Information and Presentation Assumptions

    Webcast Information and Presentation Assumptions This presentation is available in a listen only mode via the internet at http://www.streetevents.com, or http://www.alpharma.com until January 2, 2008. These materials are meant for use only in connection with the oral presentation being made by the c

  5. Slide 5: Agenda

    PRESENTERS TOPIC Agenda President &CEO Dean Mitchell Wrap Up Question & Answer Question and Answer President & CEO Dean Mitchell Strategic Progress Sr. Vice President Clinical Research & Medical Affairs Dr. Joseph Stauffer ALO-01 Phase III Clinical Results Sr. Vice President Clinical Research & Medi

  6. Slide 6: Strategic Progress

    Strategic Progress Dean Mitchell President and CEO December 18, 2007 Investor Meeting

  7. Slide 7: What I Plan to Cover

    What I Plan to Cover What we committed to last year Where we are in 2007 Where we are going in 2008 – 2012 December 18, 2007 Investor Meeting

  8. Slide 8: Overall Strategic Direction

    Overall Strategic Direction Create a high value specialty pharmaceutical business Three strong businesses with varying opportunities to achieve further growth and profitability organically and through business development activities Innovation funded from cash flows and financing Build capabilities

  9. Slide 9: 2007 Execution of the Strategy

    2007 Execution of the Strategy Pharmaceuticals: Invest to create a high value specialty pharma business Abuse-deterrent platform – positive Phase III results New product pipeline: FLECTOR ® patch, Ketoprofen in Transfersome ® gel, Tris Significant strengthening of talent and core capabilities; sales

  10. Slide 10: 2007 Milestones Scorecard

    Seven new product indications Two Chinese acquisitions Enterprise Delivering performance vs. guidance Enhanced capital structure Built capabilities 2007 Milestones -- Scorecard Launch 7 new products Leverage AD Technology to other molecules Execute Phase III clinical Program Building Credibility Thr

  11. Slide 11: Building a Top-Tier Organization in 2007

    Building a Top-Tier Organization in 2007 Increased leadership talent Additional Pharmaceutical experience on the Board – Ladell, U’Pritchard Business continuity – Campbell, Carlsson, Warner, Wrenn Key staff additions – Aigner, Spellman, Watts Infrastructure for a growing Pharmaceuticals business Sig

  12. Slide 12: Where we are going in 2008 – 2012

    Where we are going in 2008 – 2012 Continue to defend the core business Continue to execute on forward integration strategy Expand portfolio of products…seek opportunities, leverage relationships Continue organic growth programs: geographies, new indications and products Attack near-term input cost c

  13. Slide 13: Total Company: Five Year Revenue Target

    Total Company: Five Year Revenue Target Revenue $ in millions 2006 Pharmaceuticals API AHD 2011 1,000 1,500 What We Committed to Last Year December 18, 2007 Investor Meeting

  14. Slide 14: Total Company: Updated Five Year Revenue Target

    Total Company: Updated Five Year Revenue Target 2006 Pharmaceuticals API AHD 2011 1,000 1,500 Revenue $ in millions December 18, 2007 Investor Meeting

  15. Slide 15: Total Company: 2007 – 2012 Five Year Revenue Target

    Total Company: 2007 – 2012 Five Year Revenue Target Revenue $ in millions Transforming the Company Profile Targeting $1B in Revenues in 2009 2007 Pharmaceuticals API AHD 2012 500H 1,000 1,500 2,000 December 18, 2007 Investor Meeting

  16. Slide 16: Strategic Opportunities In Pharmaceuticals

    Strategic Opportunities In Pharmaceuticals Pain market has unmet needs NSAIDs Long- acting opioid abuse Significant market potential for products that address these needs Compelling clinical data on pipeline products Aggressive launch plans for FLECTOR ® Patch December 18, 2007 Investor Meeting

  17. Slide 17: Pharmaceuticals Business Update

    Pharmaceuticals Business Update Ronald Warner, PhD President Pharmaceuticals

  18. Slide 18: What We Will Talk About

    What We Will Talk About . . . KADIAN ® key metrics Current pipeline Market opportunities Topical NSAIDS Abuse Deterrence December 18, 2007 Investor Meeting

  19. Slide 19: KADIAN Revenue Trends

    $185 - $195 $160 - $165 KADIAN ® Revenue Trends $62 $102 $138 KADIAN ® Revenues Projected to Triple Over 5 Years December 18, 2007 Investor Meeting $0 $50 $100 $150 $200 2004 2005 2006 2007 Est. 2008 Guidance

  20. Slide 20: KADIAN and AVINZA TRx Trends

    KADIAN(r) and AVINZA(r) TRx Trends 2005-01 2005-02 2005-03 2005-04 2005-05 2005-06 2005-07 2005-08 2005-09 2005-10 2005-11 2005-12 2006-01 2006-02 2006-03 2006-04 2006-05 2006-06 2006-07 2006-08 2006-09 2006-10 2006-11 2006-12 2007-01 2007-02 2007-03 2007-04 2007-05 2007-06 2007-07 2007-08 2007-09 2

  21. Slide 21: What We Will Talk About

    What We Will Talk About . . . KADIAN ® key metrics Current pipeline Market opportunities Topical NSAIDs Abuse Deterrence December 18, 2007 Investor Meeting

  22. Slide 22: Total Pain Market is Over $20B and Growing

    Total Pain Market is Over $20B and Growing Source: Wolters Kluwer Health, Source ® PHAST Prescription Monthly, MAT 5/2007 Note: The pain market excludes most OTC analgesics and DMARDs. Large Market with Opportunity to Switch Generics to New Brands December 18, 2007 Investor Meeting Short-Acting Opio

  23. Slide 23: Alpharma Will Have a Presence in Over 50% of the Pain Market

    Alpharma Will Have a Presence in Over 50% of the Total Pain Market Source: Wolters Kluwer Health, Source ® PHAST Prescription Monthly, MAT 5/2007 Note: The pain market excludes most OTC analgesics and DMARDs. December 18, 2007 Investor Meeting Short-Acting Opioids $7.4B Long-Acting Opioids $3.3B Lid

  24. Slide 24: Pain Treatment Paradigm: Alpharma Portfolio

    Mild Acute Chronic Pain Treatment Paradigm FLECTOR(r) Patch Ketoprofen in Transfersome(r) gel Moderate Severe KADIAN(r) ALO-02 ALO-01 ALO-04 ALO-3a ALO-3b Abuse Deterrence Combination Pharmacologic Physical Packaging No A.D.T. Alpharma Portfolio

  25. Slide 25: December 2006 Product Pipeline

    December 2006 Product Pipeline Approved Phase 1 Target Launch Date Phase 3 Phase 2 TBD ALO-02 2009 ALO-01 Marketed KADIAN ® Capsules Beginnings of a Pipeline December 18, 2007 Investor Meeting

  26. Slide 26: Strong Pharmaceutical Product Pipeline

    Strong Pharmaceutical Product Pipeline 2011 Ketoprofen in Transfersome ® gel 2010 ALO-03b 2012 ALO-04 Approved Phase 1 Target Launch Date Phase 3 Phase 2 Q1 2009 Tirosint ® Softgel 2010 ALO-03a 2011 ALO-02 Q1 2009 ALO-01 Jan. 2008 FLECTOR ® Patch Marketed KADIAN ® Capsules Eight Potential Product La

  27. Slide 27: KADIAN NT ALO-01 Announcing

    KADIAN NT ALO-01 Announcing….

  28. Slide 28: December 18, 2007 Investor Meeting

    December 18, 2007 Investor Meeting

  29. Slide 29: EMBEDA

    EMBEDA TM

  30. Slide 30: December 18, 2007 Investor Meeting

    December 18, 2007 Investor Meeting

  31. Slide 31: What We Will Talk About

    What We Will Talk About . . . KADIAN(r) key metrics Current pipeline Market opportunities Topical NSAIDs Abuse Deterrence

  32. Slide 32: Acute Pain

    Acute Pain Acute pain states can be brief, lasting moments or hours, or they can be persistent, lasting weeks or as long as 6 months until the disease or injury heals 1,2 42% of adults in the United States experience pain daily and 89% monthly 3 99 million office visits for acute pain occurred in 20

  33. Slide 33: US NSAID/COX-2 Market Is Large and Shifting

    TRx TRx (millions) $ (billions) NSAID/COX-2 Market Prescriptions and Dollars NSAID/COX-2 Market is Large with Growth Shifting to NSAIDs US NSAID/COX-2 Market Is Large and Shifting Source: Wolters Kluwer Source ® Pharmaceutical Audit Suite PHAST Prescription Monthly December 18, 2007 Investor Meeting

  34. Slide 34: NSAID/Cox-2/Lidocaine patch Marketplace

    NSAID/Cox-2/Lidocaine patch Marketplace Product TRx Share Source: Wolters Kluwer Health, Source ® PHAST Prescription Monthly, MAT 08/07 Few Promoted Brands December 18, 2007 Investor Meeting ibuprofen 30% naproxen 15% diclofenac 6% meloxicam 9% All other NSAIDs 23% celecoxib 13% lidocaine patch 4%

  35. Slide 35: Clinical Concerns With Oral NSAIDs / Cox-2s

    1. Wilcox CM, et al. Clin Gastroenterol Hepatol . 2006;4:1082-1089. 2. Chou R, et al. Ann Intern Med . 2007;147:478-491. 3. Singh G, et al. Ann Rheum Dis 2007;66 (Suppl):509 Clinical Concerns With Oral NSAIDs / Cox-2s FLECTOR ® Patch has NSAID class labeling Nonspecific NSAIDs: upper and lower GI co

  36. Slide 36: Conclusions: Topical NSAIDs

    Conclusions: Topical NSAIDs Market for FLECTOR ® Patch is large At a time when physicians and patients concerns about NSAID/COX-2 safety are considerable, FLECTOR ® Patch could fulfill some of the unmet need for a novel pain therapy Relatively few products promoted in this space Physicians initial r

  37. Slide 37: What We Will Talk About

    What We Will Talk About . . . KADIAN(r) key metrics Current pipeline Market opportunities Topical NSAIDs Abuse Deterrence

  38. Slide 38: The Long Acting Opioid Abuse Deterrent Opportunity

    The Long Acting Opioid Abuse Deterrent Opportunity Abuse goes beyond the patient Physicians are concerned about abuse Physicians believe abuse-deterrent formulations are needed Physicians estimate significant market potential Physicians underestimate their role in abuse deterrence Opioid abuse is a

  39. Slide 39: The Hidden Faces of Opioid Abuse

    The Hidden Faces of Opioid Abuse Over 70% of Abusers Say Friends and Relatives are the Primary Source of Illicit Pain Relievers 1 1 Results From the 2006 National Survey on Drug Use and Health. December 18, 2007 Investor Meeting

  40. Slide 40: The Abuse Deterrence Concern

    The Abuse Deterrence Concern Not Concerned Somewhat Concerned Extremely Concerned 96% of Surveyed MD's Are Concerned About Abuse Source: Alpharma Primary Market Research

  41. Slide 41: Abuse-Deterrent Opioid Products Will Fulfill a Significant Unmet Need

    Abuse-Deterrent Opioid Products Will Fulfill a Significant Unmet Need Source: Alpharma Primary Market Research Importance of Having Abuse-Deterrent Opioid Formulation 79% of Surveyed MD’s Believe Having Abuse-deterrent Opioids are Very Important Not important Extremely Important December 18, 2007 In

  42. Slide 42: The Abuse Deterrent Paradox

    The Abuse Deterrent Paradox MD’s Are Concerned About Abuse, But Underestimate Their Role in The Problem Figures based on Alpharma Primary Market Research. * Long-acting opioids 79% of surveyed MD’s believe having abuse-deterrent opioids are very important 96% of surveyed MD’s are concerned about abu

  43. Slide 43: Alpharma in a Lead Position in Abuse Deterrence

    Sources: FDA, Clinicaltrials.gov, Alpharma data on file Alpharma in a Lead Position in Abuse Deterrence ALO-03b ALO-03a NDA Phase III Phase II Phase 1 Others ? ALO-04 ALO-02 Oxy-Nal (Elite) Remoxy (King) Targeting Q1 08 EMBEDA ™ Focus on Long Acting Opioid Development is Abuse Deterrence December 18

  44. Slide 44: Abuse Deterrent: Conclusions

    Abuse Deterrent: Conclusions Abuse is a significant issue in pain treatment MD’s are concerned about abuse, but need to be educated on the pathways of misuse, abuse and diversion Products with abuse deterrent features will represent a significant portion of the pain market and most of its promotiona

  45. Slide 45: Summary

    Summary Solid KADIAN ® performance Significant pipeline growth Both FLECTOR ® Patch and EMBEDA ™ on track to compete in markets of significant size Strong Pipeline in the Specialty Pain Space December 18, 2007 Investor Meeting

  46. Slide 46: The Medical Need for Topical NSAIDs

    The Medical Need for Topical NSAIDs Arthur L. Weaver, MD, MS, FACP, MACR Clinical Professor of Medicine Department of Medicine—Section of Rheumatology University of Nebraska Medical Center Omaha, Nebraska

  47. Slide 47: Overview of Oral NSAID Therapeutic Class

    Overview of Oral NSAID Therapeutic Class Current State of Therapy for Pain & Inflammation

  48. Slide 48: Total NSAID Use Increasing

    1.79 3.69 4.6 4.88 5.36 5.34 1.77 0 1 2 3 4 5 6 1999 2000 2001 2002 2003 2004 2005 NS NSAIDs COX-2 inhibitors Total NSAID Use Increasing IMS Health, IMS National Sales Perspectives TM , 2/2006 Among people ³ 65 years,70% used ³ 1 dose/week, 34% used ³ 7doses/week 1.79 1.44 1.24 1.1 1.08 1.28 1.94

  49. Slide 49: Traditional Oral NSAID Limitations: GI Toxicity

    Endoscopic injury in regular users 50%: mucosal erosions on upper endoscopy 15%-30%: gastroduodenal ulcers (45% at 6 mo) 70%: NSAID lower GI injury 23%: large lower GI erosions/ulcers Clinical upper GI Events: 2.7%-4.5% /yr Complications 1.0%-1.5% /yr Clinical lower GI events: 0.19%-0.89% /yr Intest

  50. Slide 50: Risk Factors: Oral NSAID-Associated Ulcer Complications

    2.2 5.6 6.1 6.4 7 9 13.5 0 15 Steroids Age >70 years Past uncomplicated ulcer Anticoagulant High-dose NSAIDs Multiple NSAIDs Past complicated ulcer Increased Risk (Odds Ratio) 5 10 Risk greatest within first month of use Gabriel SE, et al. Ann Intern Med. 1991;115:787-96. Garcia-Rodriguez LA, et al.

  51. Slide 51: Strategies to Minimize Oral NSAID-Gastropathy

    Identify individuals with risk factors for adverse events Stop NSAID Use non-NSAID analgesic Decrease NSAID dose Use lower-risk NSAID COX-2 selective inhibitor Prescribe medical co-therapy Proton pump inhibitor Prostaglandin analog: misoprostol In patients with very high risk, one protective strateg

  52. Slide 52: Risk Of GI Bleed With NSAIDs or Coxib

    Aspirin alone 3.2 Combination 15.4 Aspirin alone 2.8 Combination 15.8 1,034 cases; 2,068 controls Risk Of GI Bleed With NSAIDs or Coxib Drug Adjusted Relative Risk NSAID alone 4.7 COX-2 alone 1.3 Lanas A, García-Rodriguez LA. Gastroenterology . 2003;124:(Suppl 1):A93.

  53. Slide 53: CV Risk With Celecoxib

    Non-ASA users (n = 1421) 1.1% 2.6% # deaths/total pts 5/466 25/955 ASA users (n = 614) 0.9% 3.5% # deaths/total pts 2/213 14/401 Deaths from CV causes in APC Trial CV Risk With Celecoxib Placebo Celecoxib Solomon SD, et al. N Engl J Med. 2005;352:1071-80.

  54. Slide 54: Balance GI & CV Risk

    Complicated GI events with COX-2 than NSAIDs Serious CV events occurred at ~ equal rates For COX-2, in complicated upper GI events numerically greater than any CV events For every 1,000 patients treated for 1 yr with a COX-2 vs NSAID: 8 fewer upper GI complications 1 more fatal or nonfatal heart att

  55. Slide 55: Addressing Unmet Needs

    NSAIDs & COX-1 sparing agents proven efficacy Treat edema & hypertension aggressively Acetaminophen efficacy/safety? (CV, GI, BP) COX-1 sparing agents & NSAIDs may CV risk with prolonged use, high dosage, & in patients with CV risk Assess both CV & GI risk before initiating Larger trials, longer dur

  56. Slide 56: Addressing Unmet Patient Needs

    Topical NSAIDs Applied directly at site of pain Compared with transdermal applied away from painful site Available in EU & Asia >20 yrs Compounding Many in development 2 approved: FLECTOR ® patch: acute sprains, strains contusions Diclofenac gel: pain of osteoarthritis Addressing Unmet Patient Needs

  57. Slide 57: FLECTOR Patch Clinical Data

    Joseph W. Stauffer, DO Chief Medical Officer Sr. Vice President Clinical Research & Medical Affairs Adjunct Assistant Professor Johns Hopkins University Hospital Department of Anesthesiology & Critical Care Medicine Division of Pain Medicine FLECTOR ® Patch Clinical Data

  58. Slide 58: Overview

    Overview Regulatory and Worldwide Safety Status Pharmacokinetic Data Efficacy Data Safety Data

  59. Slide 59: Regulatory Status

    Regulatory Status The FLECTOR ® Patch (diclofenac epolamine topical patch) was approved by the FDA in 2007 for the indication of: Topical treatment of acute pain due to minor strains, sprains, and contusions First approved in Switzerland in 1993. Subsequently approved in 39 countries (15 in Western

  60. Slide 60: Worldwide Safety Experience

    Worldwide Safety Experience Over 6 million unique patient exposures No deaths 133 adverse events reported in 81 patients 2001-2006, 27 adverse events related to FLECTOR ® Patch with most related to application site conditions (eg, skin rash) Alpharma Pharmaceuticals LLC; data on file.

  61. Slide 61: Clinical Trials Overview

    Clinical Trials Overview Study Indication Duration/ Regimen Number of Subjects Primary Endpoint Plasma diclofenac level 4 days/BID NA Comparative bioavailability VAS pain at Day 14 14 days/BID Minor Soft Tissue Injury Pivotal 1 (14-day study) VAS pain at Days 3 & 7 7 days/QD Minor Ankle Sprain Ankle

  62. Slide 62: Pharmacokinetics and Comparative Bioavailability

    Pharmacokinetics and Comparative Bioavailability Comparative bioavailability of FLECTOR ® Patch (diclofenac epolamine) and VOLTAREN ® (oral diclofenac sodium) in healthy volunteers Alpharma Pharmaceuticals LLC; data on file.

  63. Slide 63: Mean Plasma Concentration Over Time

    Mean Plasma Concentration Over Time FLECTOR ® Patch and VOLTAREN ® Oral Tablets Mean Plasma Concentration (ng/mL) Time (hours) FLECTOR ® Patch VOLTAREN ® Oral Tablets Alpharma Pharmaceuticals LLC; data on file. 0.01 0.1 1000 10000 400x Lower Systemic Blood Level

  64. Slide 64: Comparison Between Plasma and Synovial Fluid

    Comparison Between Plasma and Synovial Fluid with FLECTOR ® Patch Four hours after the application of FLECTOR ® Patch, a statistical difference between plasma and synovial fluid diclofenac concentrations was observed (p<0.05), the average amount of drug reaching the synovial fluid being 35.9% of tha

  65. Slide 65: 7-Day Study

    7-Day Study A controlled double-blind clinical study on the efficacy and safety of FLECTOR ® Patch versus placebo in minor ankle sprain Joussellin. J Traumatol Sport. 2003;20:1S5-1S9.

  66. Slide 66: 7-Day Study: Decrease in Median Pain on First Day

    7-Day Study: Decrease in Median Pain on Active Mobilization (%) Measured by Last VAS Value on First Day of Application * * * FLECTOR ® Patch placebo patch *Indicates Statistically Significant Difference ( P <0.05). Alpharma Pharmaceuticals LLC; data on file. -25 -20 -15 -10 -5 Hours after first appl

  67. Slide 67: 7-Day Study: Decrease in Median Pain Days 0–3

    7-Day Study: Decrease in Median Pain on Active Mobilization (%) Measured by Last VAS Value on Days 0–3 * * Decrease in Spontaneous Pain (%) Day Day Day Day * * * * 8 PM 8 AM Noon 8 PM 8 AM Noon 8 PM 8 AM Time Period *Statistically Significant Difference ( P <0.05). Alpharma Pharmaceuticals LLC; data

  68. Slide 68: 7-Day Study: Decrease in Pain Days 3 & 7

    7-Day Study: Decrease in Pain on Active Mobilization (%) Measured by Last VAS Value on Days 3 & 7 *Statistically Significant Difference ( P <0.05). Alpharma Pharmaceuticals LLC; data on file. * * Day 7 Consultation Day 3 Consultation FLECTOR ® Patch placebo patch -95 -90 -85 -80 -75 -70 -65 Decrease

  69. Slide 69: 14-Day Study (Sport-2)

    14-Day Study (Sport-2) A randomized, double-blind study of the analgesic efficacy and safety of the FLECTOR ® Patch in minor sports injury Alpharma Pharmaceuticals LLC; data on file.

  70. Slide 70: 14-Day Study (Sport-2): Time to Pain Resolution

    14-Day Study (Sport-2): Time to Pain Resolution Alpharma Pharmaceuticals LLC; data on file. P =0.009 FLECTOR ® Patch (median=8.8 days) placebo patch (median=12.4 days) Study Day Percent With Success

  71. Slide 71: Pivotal (14-Day Study)

    Pivotal 1 (14-Day Study) A randomized, double-blind, placebo-controlled study of the analgesic efficacy and safety of the diclofenac epolamine patch in minor soft tissue injury Alpharma Pharmaceuticals LLC; data on file.

  72. Slide 72: 14-Day Study: Primary Efficacy

    69 14-Day Study: Primary Efficacy *Statistically Significant Result Relative to Placebo Group (P<0.05). Alpharma Pharmaceuticals LLC; data on file. VAS Score as a Proportion of Baseline (Mean ? Standard Error) * 0.50 0.48 0.46 0.44 0.42 0.40 0.38 0.36 placebo patch FLECTOR(r) Patch

  73. Slide 73: FLECTOR Patch: 14-Day Study Time to Injury Resolution

    FLECTOR ® Patch: 14-Day Study Time to Injury Resolution FLECTOR ® Patch placebo patch Median Time to Pain Resolution Alpharma Pharmaceuticals LLC; data on file. [Beks P, et al. Manuscript in preparation]. P =0.007 5.5 7.5

  74. Slide 74: 14-Day Studies: Time to Injury Resolution

    14-Day Studies: Time to Injury Resolution Alpharma Pharmaceuticals LLC; data on file. Ekman EF, et al. Am J Orthop. 2002;31:445-451. ® P =0.007 Pivotal 1 (2004) Ekman (2002) 5.5 7.5 FLECTOR Patch placebo patch Celecoxib Ibuprofen Placebo

  75. Slide 75: Safety Data From US Clinical Trials

    Safety Data From US Clinical Trials FLECTOR(r) Patch (N=572) placebo patch (N=564) Application Site Conditions Pruritus Dermatitis Burning Other 64 (11%) 31 (5%) 9 (2%) 2 (<1%) 22 (4%) 70 (12%) 44 (8%) 3 (<1%) 8 (1%) 15 (3%) Gastrointestinal Disorders Nausea Dysgeusia Dyspepsia Other 49 (9%) 17 (3%)

  76. Slide 76: Overall Conclusions

    73 Overall Conclusions Efficacy The FLECTOR(r) Patch is efficacious in relieving acute pain associated with minor injuries such as sprains, strains, and contusions Pain relief with the FLECTOR(r) Patch occurred as early as 4 hours after the first application (7-day study) Time to pain resolution (4

  77. Slide 77: FLECTOR Patch Launch

    Scott Shively Sr. Vice President Sales & Marketing FLECTOR ® Patch Launch

  78. Slide 78: FLECTOR Patch Commercial Launch Plan

    FLECTOR® Patch Commercial Launch Plan Introduction to the Product Summary of Market Research Promotional Campaign Marketing Pre-Launch and Launch Plans Sales Force Strategy Managed Care Strategy

  79. Slide 79: Critical Success Factors to Build Pain Franchise

    Critical Success Factors to Build Pain Franchise Customer Understanding Proactive with Competition Creativity Executional Excellence Highly Strategic Approach People

  80. Slide 80: Flector (diclofenac epolamine topical patch) 1.3%

    Flector; (diclofenac epolamine topical patch) 1.3% @ ALPHARMA. Pharmaceuticals

  81. Slide 81: FLECTOR Patch: Characteristics

    FLECTOR ® Patch: Characteristics 10 cm X 14 cm Patch Felt backing (against clothing) Adhesive surface (against skin) Transparent release liner (removed prior to application)

  82. Slide 82: FLECTOR Patch: Commercial Packaging

    FLECTOR ® Patch: Commercial Packaging Single patch 5 patches in a pouch 6 pouches in a box

  83. Slide 83: FLECTOR Patch Primary Market Research

    FLECTOR ® Patch Primary Market Research Project Objective FLECTOR ® patch has been extensively tested in market research with over 530 physicians in addition to multiple marketing advisory boards Pain Product Profile Evaluation Obtain reactions to topical pain products FLECTOR® Patch Positioning Stu

  84. Slide 84: Physicians Are Very Responsive to FLECTOR Patch

    N=245 Very unfavorable Very favorable Overall Impression of FLECTOR(r) Patch Profile Physicians Are Very Responsive to FLECTOR(r) Patch 1 2 3 4 5 East 0 0.020408163 0.179591837 0.636734694 0.163265306

  85. Slide 85: Market Research Summary of Key Findings

    FLECTOR® Patch Market Research Summary of Key Findings FLECTOR® Patch product profile elicits extremely favorable reactions from physicians in all market research studies Physicians would allocate to FLECTOR® Patch a significant share of their acute, mild-to-moderate pain patients that would have be

  86. Slide 86: Market Research Key Findings (continued)

    FLECTOR® Patch Market Research Key Findings (continued) Several key potential advantages of the FLECTOR ® Patch were identified Safe/well tolerated – comparable to placebo Minimal systemic absorption Effective analgesia Analgesia directly at the painful site (due to the topical application) Some phy

  87. Slide 87: Market Research Evaluation Verbatims

    FLECTOR® Patch Market Research Evaluation Verbatims “ I like the idea that it is a non-steroidal in the form of a patch. Because there is minimal systemic absorption , you are bypassing a lot of side effects that would be caused otherwise.” RHEUMATOLOGIST “ It is a familiar drug, so it gives you som

  88. Slide 88: The 1st and only topical NSAID Patch

    The 1st and only topical NSAID Patch Introducing Draft concept tested in marketing research. Currently under review at DDMAC and may not be use for promotional purposes

  89. Slide 89: Launching FLECTOR Patch With Channel Synergies

    Launching FLECTOR ® Patch With Channel Synergies PR Sales Branded Medical Education Promotion LAUNCH MSL Round Tables Managed Markets

  90. Slide 90: FLECTOR Patch Pre-Launch Activities

    Aug 07’ Sep 07’ Oct 07’ Nov 07’ Dec 07’ Jan 08’ Positioning and Concept Development Sales Aid and Journal Ad Testing and Development Develop Pricing and Managed Care Strategy Flector.com Website Recruit Sales Force Sales Force Training Amer. College of Rheumatology Regional Ad Boards FLECTOR® Patch

  91. Slide 91: Creating Momentum Prior to Launch

    Creating Momentum Prior to Launch Journal Advertisements Total Hits = 500,000 Direct Mail – Alert Marketing PCP Reach = 77,000 NP/PA Reach = 99,000 Regional Advisory Boards Nationwide Attendees = 280+ New England Journal of Medicine American Medical News Internal Medicine News Family Practice News P

  92. Slide 92: Sales Force Strategy: Call Plan

    Sales Force Strategy FLECTOR® Patch Call Plan Decile 10 Alpharma Sales Force CSO Decile 1 Decile 5 Efficient Promotional Targeting

  93. Slide 93: Efficient Sales Force Overlap and Coverage

    Efficient Sales Force Overlap and Coverage of the FLECTOR ® Patch and KADIAN®/EMBEDA™ Markets High Potential KADIAN®/EMBEDA ™ Targets 42,420 High Potential FLECTOR® Patch Targets 47,944 42,364 5,580 48,000 Targets FLECTOR® Patch Targets KADIAN® Targets Overlapping Targets Efficient Targeting; 90% Ov

  94. Slide 94: Building the Sales Force – Ramped Up to Launch

    Building the Sales Force – Ramped Up to Launch Alpharma Sep 1, 2007 Jan 7, 2008 CSO # Reps Primary Detail Capacity Total For Launch Alpharma + = 319,000/yr 889,000/yr

  95. Slide 95: Sales Force Expansion Complete

    Sales Force Expansion Complete 224 new sales reps hired Average of 8 years sales experience Average of 5 years of pharma sales experience 46% have big pharma experience Companies recruited from include: Abbott, Astra-Zeneca, BMS, Cephalon, Eisai, Eli Lilly, Endo, Glaxo Smith Kline, J&J, King, Ligand

  96. Slide 96: Managed Care (Payor) Response to FLECTOR Patch

    Managed Care (Payor) Response to FLECTOR® Patch Most participants had a neutral to favorable reaction to the FLECTOR® Patch, focusing mostly on its route of administration and the minimal systemic absorption. Very unfavorable Unfavorable Neutral Very Favorable Favorable n=30 Overall, participants fe

  97. Slide 97: Managed Care Strategy

    Managed Care Strategy Achieve Commercial Managed Care Access for FLECTOR® Patch Tier two status to be achieved in significant number of targeted plans. Access to more than 110 million commercial lives Seek Medicare Coverage for FLECTOR® Patch Plans will act on new products within 180 days of commerc

  98. Slide 98: Distribution Plan

    Distribution Plan Wholesalers Launch deal and documentation sent out to wholesalers 11/15 Orders received 12/3-12/14 Began shipping 12/17 All wholesalers will have product by 12/19. Retailers Auto-ship program presented to all accounts All major national chains (e.g. Walgreens) and key regional chai

  99. Slide 99: FLECTOR Patch Conclusion

    FLECTOR® Patch…Conclusion Marketing Research has indicated very positive acceptance by physicians Sales Force is recruited and in training Pre-marketing plan executed, and awareness is building Initial Managed Care meetings underway – positive early acceptance Promotional materials under review at D

  100. Slide 100: Grow KADIAN Business

    Grow KADIAN Business Crisp Messaging & Targeted Tools Broader Target Audience With 400 Reps More Diverse Target Audience Second Position Detail IC Plan Aligned To Support Both KADIAN® as well as FLECTOR® Patch

  101. Slide 101: Building the Pain Franchise one Specialty-Buster at a Time

    Building the Pain Franchise one “Specialty-Buster” at a time EMBEDA ™

  102. Slide 102: EMBEDA Overview

    EMBEDA ™ Overview Joseph W. Stauffer, DO Chief Medical Officer Senior Vice President Clinical Research & Medical Affairs Alpharma Pharmaceuticals, LLC Adjunct Assistant Professor Johns Hopkins University Hospital Department of Anesthesiology & Critical Care Medicine Division of Pain Medicine

  103. Slide 103: What we'll talk about

    What we’ll talk about… EMBEDA ™ Technology Pivotal Efficacy Data Pivotal Safety Data to Date New Abuse Deterrent Data Summary

  104. Slide 104: How Does the EMBEDA Abuse-deterrent Technology Work?

    2. If EMBEDA ™ is crushed, chewed or extracted: A. the naltrexone (opioid antagonist) releases and mixes with morphine B. the morphine-naltrexone mixture is intended to prevent euphoria from morphine by competing for the same opioid receptor in the brain…thus deterring abuse of the product 1. If tak

  105. Slide 105: Pivotal Efficacy Study

    Pivotal Efficacy Study Objective Evaluate efficacy and safety of EMBEDA ™ vs. placebo for chronic moderate to severe pain Study Design Conducted Under Special Protocol Assessment (SPA) Open-label titration phase Double-blind maintenance phase

  106. Slide 106: Assessments

    Assessments Primary Efficacy Measure Change from baseline to the end of maintenance phase Brief Pain Inventory (BPI) score of average pain Secondary Endpoints BPI Average Pain from Daily Diary WOMAC Pain Subscale WOMAC Composite Score Medical Outcomes Study (MOS) sleep scale Beck Depression Inventor

  107. Slide 107: Efficacy – Primary Endpoint

    Efficacy – Primary Endpoint Mean Change From in-Clinic Baseline BPI Average Pain Score Mean Change From Baseline BPI Average Pain Score *PI scale: 0 = no pain, 10 = pain as bad as you can imagine p=0.04 ™ 2.9 3.1 3.2 3.3 3.4 3.5 3.6 Randomization Baseline 12 Weeks EMBEDA Placebo

  108. Slide 108: BPI Average Pain Score Daily Diary

    Taper period BPI Average Pain Score Daily Diary p=0.001 p=0.005 p=0.001 p=0.001 p=0.001 p=0.007 *PI scale: 0 = no pain, 10 = pain as bad as you can imagine ™ 0.5 1.5 2.5 3.5 Week 0 Week 6 Week 12 Placebo EMBEDA

  109. Slide 109: WOMAC Pain Subscale Score

    Taper period WOMAC Pain Subscale Score p=0.05 p=0.02 p=0.02 p=0.003 ™ Week 0 Week 6 Week 12 Placebo EMBEDA

  110. Slide 110: WOMAC Composite Score

    Taper period WOMAC Composite Score p=0.04 p=0.03 p=0.04 p=0.03 p=0.02 ™ Week 0 Week 6 Week 12 Placebo EMBEDA

  111. Slide 111: Secondary Endpoints

    Secondary Endpoints ITT Population Endpoint, Mean (+-SD) Change from First Visit to Week 12 Change from First Visit to Week 12 Change from First Visit to Week 12 Endpoint, Mean (+-SD) Placebo N=173 EMBEDA N=170 p- value BPI diary average pain score 0.8 (1.94) 0.3 (1.91) 0.0048 WOMAC Pain Subscale 5.

  112. Slide 112: At Three Months, No Statistical Difference

    Study 301 Safety Population Deaths, n (%) 0.8185 9 (5.3) 11 (6.4) Severe TEAEs , n (%) 0.8324 12 (7.0) 11 (6.4) TEAEs leading to discontinuation, n (%) 0.1932 56 (32.7) 45 (26.0) Drug-related TEAE,* n (%) 0.3909 91 (51.2) 84 (48.6) Any treatment-emergent adverse event (TEAE) , n (%) p- value EMBEDA

  113. Slide 113: Pivotal Safety Study

    Pivotal Safety Study 302 Objective Evaluate long-term safety of EMBEDA ™ over 12 months in patients with chronic moderate to severe pain Study Design Phase 3, multi-center, open-label, long-term study Dose titration Initial dose: Opioid-naïve subjects 20 mg BID Subjects who took opioids previously d

  114. Slide 114: Patient Global Assessment of EMBEDA

    Patient Global Assessment of EMBEDA(tm) ITT Population <80mg 80-120mg >120mg Overall Good+Very good+Excellent 95 90 88.9 93.1 Excellent 37.2 32.5 25.9 34.6 Very good 39.7 40 40.7 39.9 Good 18.2 17.5 22.2 18.6 Fair 5 10 7.4 6.4 Poor 0 0 3.7 0.5 6 Months % of Patients

  115. Slide 115: Naltrexone Levels Measured

    Naltrexone Levels Measured Highly sensitive assay No appreciable naltrexone detected Similar outcome to Phase II No correlation between naltrexone level and clinical effect

  116. Slide 116: Abuse Deterrent Study Design

    Phase 1 Study 205 Objective Determine relative pharmacodynamic effects and safety of (1) crushed and whole ALO-01 compared to Morphine Sulfate IR and placebo and of (2) crushed ALO-01 to whole ALO-01 Study Design Screening/Qualifying period (up to 56 days) 3-night inpatient double-blind qualifying s

  117. Slide 117: Study Pharmacodynamic

    Study 205 Pharmacodynamic Cole/ARCI Stimulation Euphoria Peak Plasma Morphine Concentration, t=1.5 h 0.755 Whole ALO-01 – Placebo @ 1.5 h 0.089 Crushed ALO-01 – Placebo @ 1.5 h <.001 Morphine IR – ALO01 whole @ 1.5 h <.001 Morphine IR – ALO-01 crushed @ 1.5 h <.001 Morphine IR – Placebo @ 1.5 h Trip

  118. Slide 118: Study Pharmacodynamic

    Study 205 Pharmacodynamic <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 Morphine IR - ALO-01 whole <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 Morphine IR - ALO-01 crushed <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 Morphine IR – Placebo Treatment effect 1.5 h <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.00

  119. Slide 119: Summary

    Summary EMBEDA ™ …if taken as directed significantly decreases chronic pain Is safe and well tolerated with adverse events consistent with morphine and other Long-acting opioids EMBEDA ™ …if tampered with Demonstrates Significant Abuse-Deterrent Features

  120. Slide 120: Wrap Up

    Wrap Up Dean Mitchell President and CEO

  121. Slide 121: Strategic Direction

    Strategic Direction Create a high value specialty pharmaceutical business Three strong businesses with varying opportunities to achieve further growth and profitability organically and through business development activities Innovation funded from cash flows and financing Build capabilities to drive

  122. Slide 122: As We Enter 2008

    As We Enter 2008 Significant market opportunities Targeted investments to drive sustainable growth Rigorous operating cost discipline and cash generation Strong financial position Continuous focus on capital structure and portfolio to maximize shareholder value Positioned for Growth and Value Creati

  123. Slide 123: 2008 Targeted Milestones

    2008 Targeted Milestones Pharmaceuticals API Animal Health FLECTOR(r) Patch launch KADIAN(r) revenue growth EMBEDA(tm) NDA filing Leverage abuse deterrent technology to other molecules Continue vancomycin growth Commercialize injectable production Commercialize Chinese vancomycin capacity Introduce

  124. Slide 124: To Sum Up

    Strategic transformation… entering second year of execution Increased confidence in strategic potential and our ability to execute based on strong 2007 performance To Sum Up… Investing to Create Significant Shareholder Value

  125. Slide 125: Questions and Answers

    Questions and Answers December 18, 2007 Investor Meeting

Alpharma — Investor Day (December 2007) on 6ix